On Thursday, ImmunoGen, Inc. (NASDAQ:IMGN)’s shares declined -4.08% to $12.47.
ImmunoGen, Inc. ( IMGN), declared that investors, journalists and the general public are invited to listen to a live webcast of the Company’s analyst and investor community meeting on September 18, 2015.
The event will focus on ImmunoGen’s strong foundation for growth, counting the advancement of its multi-product pipeline, its proprietary technology that is enabling the development of novel anticancer therapies and the Company’s core competencies that position it for success.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia.
Avnet, Inc. (NYSE:AVT)’s shares dropped -2.39% to $41.62.
Avnet Electronics Marketing, an operating group of Avnet, Inc. (AVT), released the new Zynq®-7000 All Programmable SoC/Analog Devices Intelligent Drives Kit II. The kit is designed to provide a flexible platform for motor control and industrial networking development in sectors counting industrial automation, smart energy, medical and embedded systems. This evolution of the original Zynq-7000 All Programmable SoC/Analog Devices Intelligent Drives Kit offers improved performance features counting greater precision data converters from Analog Devices, higher frequency direct drive of the H-bridge power stages and simultaneous drive of two motors, counting bipolar steppers or BLDC with electronic brake.
Avnet, Inc., together with its auxiliaries, distributes electronic components, enterprise computer and storage products, IT solutions and services, and embedded subsystems in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. It operates through two segments, Electronics Marketing (EM) and Technology Solutions (TS).
At the end of Thursday’s trade, Diplomat Pharmacy Inc (NYSE:DPLO)‘s shares dipped -8.96% to $41.36.
Diplomat Pharmacy Inc (DPLO) declared its 2015 satisfaction survey results, receiving a 100 percent patient satisfaction rating for over 10 years in a row. Headquartered in Enfield, Connecticut, AHF is a specialty pharmacy that provides homecare pharmacy services to patients living with hemophilia, von Willebrand disease and other bleeding disorders.
AHF has always taken great pride in the quality of services offered to the hemophilia community by providing assistance to patients in overcoming the medical, economic and societal barriers often faced by those living with hemophilia and other bleeding disorders.
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, in addition to clinical and administrative support services to hospitals and health systems.
Xylem Inc (NYSE:XYL), ended its Thursday’s trading session with -1.48% loss, and closed at $32.66.
Xylem Inc. (XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, stated second quarter 2015 net income of $74 million, or $0.41 per share. Not taking into account restructuring and realignment charges and other special items, adjusted net income was $78 million or $0.43 per share, down 10 percent from the comparable period in 2014, but up two percent not taking into account the impact of foreign exchange translation. Second quarter revenue was $920 million, an enhance of one percent organically, reflecting strength in the commercial and public utility end-markets. Second quarter operating margin was 11.3 percent, down 20 basis points from the preceding year. Adjusted operating margin was 12.0 percent, flat year-over-year not taking into account the 40-basis-point impact of foreign exchange translation. This result reflects volume leverage and lower expenses offset by inflation, the divestiture of a business and unfavorable mix.
Full-year 2015 Outlook
Xylem is narrowing the range of its full-year outlook, which continues to reflect ongoing foreign exchange fluctuations. Xylem continues to expect full-year 2015 revenue of about $3.7 billion, a decrease of six to seven percent from the full-year 2014 results. On an organic basis, Xylem now anticipates to generate revenue growth of about one to two percent.
Full-year 2015 adjusted operating income is now predictable to be in the range of $470 million to $483 million, resulting in adjusted earnings per share of $1.82 to $1.87. Not taking into account the projected unfavorable impact of foreign exchange translation, Xylem’s adjusted earnings per share growth expectations are in the range of six to seven percent over the comparable full-year 2014 results. The Company’s outlook for projected restructuring and realignment costs of $20 million for the year is unchanged.
Xylem Inc. engages in the design, manufacture, and application of engineered technologies for the water and wastewater applications. The company operates in two segments, Water Infrastructure and Applied Water. The Water Infrastructure segment offers various products, counting water and wastewater pumps, treatment and testing equipment, and controls and systems, in addition to filtration, disinfection, and biological treatment equipment under the Flygt, WEDECO, Godwin, WTW, Sanitaire, YSI, and Leopold names for transportation, treatment, and testing of water and wastewater for public utilities and industrial applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
